SCHEMBL13755151

SCHEMBL13755151

CCOc1cc(Cl)c(CC)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.44
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 3/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.35
LTA4H P09960 2/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
MEN1 O00255 2/20 0.33
NFKB1 P19838 1/20 0.33
NPC1 O15118 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23378586 0.79 L3MBTL1 (0.38) TDP1KMT2AL3MBTL1KDM4EMAPT
SCHEMBL8415344 0.79 ALDH1A1 (0.46) CYP3A4KMT2AKDM4EMAPT
SCHEMBL28069071 0.79 NQO1 (0.46) NQO1TSHRTDP1TP53CYP3A4
SCHEMBL15334797 0.79 NQO1 (0.46) NQO1TSHRTDP1TP53CYP3A4
SCHEMBL15771837 0.77 TSHR (0.46) NQO1TSHRTDP1TP53CYP3A4
SCHEMBL4878664 0.76 NQO1 (0.42) NQO1TSHRTDP1TP53CYP3A4
SCHEMBL15445801 0.76 NQO1 (0.42) NQO1TSHRTDP1TP53CYP3A4
SCHEMBL4678875 0.75 NQO1 (0.34) NQO1TDP1KDM4EMAPT
SCHEMBL16575424 0.74 NQO1 (0.46) NQO1TSHRTDP1TP53CYP3A4
SCHEMBL18071781 0.74 NQO1 (0.46) NQO1TSHRTDP1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120329782-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2012-12-27 US disclosed
US-20090197869-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION, A DELAWARE CORPORATION 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329782-A1 AZEPINE INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 NQO1 3582/4885TSHR 3268/4885TDP1 1627/4885
US-20090197869-A1 AZEPINE INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 NQO1 3582/4885TSHR 3268/4885TDP1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.